Metrics to compare | ONCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.1x | −2.4x | −0.4x | |
PEG Ratio | 0.85 | 0.01 | 0.00 | |
Price/Book | 113.9x | −2.3x | 2.6x | |
Price / LTM Sales | 402.3x | 0.7x | 3.0x | |
Upside (Analyst Target) | - | 287.1% | 50.7% | |
Fair Value Upside | Unlock | −18.6% | 7.2% | Unlock |
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company’s lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.